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group (32 patients) and placebo group (34 patients). Baseline clinical,
angiographic and periprocedural characteristics were not signiﬁcantly
different between the atorvastatin and control group except for age
and length of stent used, but they didn’t inﬂuence the IMR value.
There were no signiﬁcant differences in regard of fractional ﬂow
reserve (FFR) (0.94 vs. 0.96, p ¼ 0.39), coronary ﬂow reserve (CFR) (1.1
vs. 1.2, p ¼ 0.09) and also IMR (41.54[12.8-198.2] vs. 41.60 [10.4 –
200.3], p ¼ 0.61) between both groups.
CONCLUSION Administration of high loading dose of atorvastatin (80
mg) before primary PCI in STEMI patients didn’t improve microvas-
cular perfusion as measured by index of microvascular resistance
compare to placebo.ADJUNCTIVE PROCEDURES: THROMBECTOMY,
PLAQUE MODIFICATION, OTHERS (TCTAP A-021)
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BACKGROUND Treatment of calciﬁed lesions with balloon angioplasty
has been associated with a low success rate and high procedural
complications. Rotational atherectomy (RA) improved acute results,
but a high restenosis rate remained a problem. Therefore, the purpose
of this study was to evaluate the clinical and angiographic outcome of
patients with complex and calciﬁed lesions treated with a combination
of RA and second-generation drug-eluting stent (DES) implantation.
METHODS Consecutive 55 patients received combination therapy of
RA and second-generation DES implantation at de novo lesion of
native coronary artery with severe calciﬁcation between June 2009
and December 2012. Zotarolimus-eluting stents (ZES), biolimus-
eluting stent (BES), and everolimus-eluting stents (EES) were used in
14, 7, and 34 patients, respectively. 39 patients (ZES, BES, and EES
were used in 12, 6, 21 patients) received one-year follow-up angiog-
raphy. The clinical and angiographic outcome was compared among
those 3 groups of different DES.
RESULTS Only one patient was dead (a cause was unknown). Target
lesion revascularization (TLR) rate was 0% among 3 groups. The late
loss was larger in ZES than in BES or EES (ZES vs. BES vs. EES:
0.370.20mm vs. 0.200.10mm vs. 0.160.15mm, p<0.05).
CONCLUSION The clinical outcome of 3second-generation DES used
in combination with RA was very good, although the culprit lesions
were complex with severe calciﬁcation. Combination therapy of RA
and second-generation DES appeared acceptable.ANTIPLATELET AGENTS AND ANTICOAGULANTS
(TCTAP A-022 TO TCTAP A-025, TCTAP A-136)
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BACKGROUND It has been well known that new P2Y12 receptor
inhibitors (RI; prasugrel or ticagrelor) could improve clinical out-
comes in patients with acute myocardial infarction (AMI). However,there were little data about the impact of new P2Y12 RI in Korean
patients with AMI. Therefore, we compared the short-term clinical
outcomes between new P2Y12 RI and clopidogrel in patients with
AMI undergoing successful percutaneous coronary intervention
(PCI).
METHODS Between November 2011 and August 2014, a total of 4,029
patients (3,186 patients were prescribed clopidogrel and 843 patients
new P2Y12 RI [474 patients prasugrel and 369 patients ticagrelor])
with AMI undergoing successful PCI were included from Korea Acute
Myocardial Infarction Registry-National Institute of Health. The pa-
tients older than 75 years, weight< 60 kg, or with a history of stroke
and with in-hospital switching among 3 antiplatelet agents were
excluded. The propensity score matching (802 pairs) were performed
in order to compare the in-hospital clinical outcomes between new
P2Y12 RI and clopidogrel after adjusting for baseline clinical and
procedural confounders.
RESULTS P2Y12 reactivity unit by the Verify Now P2Y12 test was
77.574.50 in new P2Y21 RI and 212.280.72 in clopidogrel. The in-
cidences of Thrombolysis In Myocardial Infarction (TIMI) major
bleeding and minor bleeding were signiﬁcantly higher in new P2Y12
RI than clopidogrel (3.1% vs. 1.1%,p¼0.006; 4.1% vs. 1.9%, p¼0.008).
However, there were no signiﬁcant differences in in-hospital mor-
tality and the composite of cardiac death, MI or stroke during hospital
stay between new P2Y12 RI and clopidogrel (1.0% vs. 0.7%, p¼0.591;
1.0%vs. 1.1%, p¼0.807). Also, no difference in the composite of car-
diac death, MI, stent thrombosis, target vessel revascularization or
stroke at 6 months was observed in both group (1.0% vs. 2.3%,
p¼0.114). On multivariate analysis, use of statin, TFI vs. TRI and use
of glycoprotein IIb/IIIa inhibitors were independent predictors of the
composite of cardiac death, MI, stent thrombosis, stroke or TIMI
major bleeding (odd ratio [OR]¼0.187; 95% conﬁdence interval
[CI]¼0.083-0.422, OR¼10.811; 95%CI¼2.560-45.652,OR¼2.174; 95%
CI¼1.103-4.284).
CONCLUSION Our study shows that new P2Y12 RI had similar efﬁcacy
for preventing ischemic events compared with clopidogrel, but an
increased bleeding complications. The large scale, long-term, ran-
domized trials should be needed to assess the safety of P2Y12 RI for
Korean AMI patients undergoing successful PCI.TCTAP A-023
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BACKGROUND Introduction- The response to Clopidogrel, a pro-drug
requiring CYP450 biotransformation is not uniform. Data suggest its
pharmacologic effect varies based on CYP2C19 genotype, but there is
uncertainty regarding the clinical impact of platelet function test and
genotyping.
Objectivedin this study on patients with coronary artery disease
treated with percutaneous coronary intervention (PCI), we evaluated
the clinical impact of platelet reactivity measured by platelet function
test and gene polymorphism assessed by genotyping in Korean
patients.
METHODS A Database search 0f Chungbuk Regional cardiovascular
center was conducted (January 2010-August 2014). Platelet function
test and genetic studies were included where clopidogrel was initiated
in conventional PCI in the ischemic heart disease.
RESULTS A total of 567 patients with coronary artery disease treated
by PCI were enrolled. The level of P2Y12 reaction unit (PRU) of the
patients with CYP*2 or*3 heterozygote or CYP*2/*2 or *2/*3 or *3/*3
was signiﬁcantly higher than with CYP*1/*1 or *1/*17(20986.8
(extensive metabolizers, EMs) vs. 22887.1 (intermediate metabo-
lizers, IMs) vs. 24384.4 (poor metabolizers, PMs), p ¼0.006, 1 way
ANOBA). The frequency of high on-treatment clopidogrel platelet
reactivity (HPR) was also signiﬁcantly higher in IMs and PMs (p ¼
0.002). At1-year follow-up, the major cardiac adverse event occurred
more frequently inpatients with high on-treatment clopidogrel
platelet reactivity compared with patients without high on-treatment
clopidogrel platelet reactivity, when platelet function was evaluated
with the Verify Now P2Y12 assay (23 (9.3%) vs. 27 (7.5%), p¼0.27)
without statistical signiﬁcance. Kaplan-Meier test for MACE-free
survival did not showed signiﬁcant difference in survival analysis
between High on-treatment clopidogrel platelet reactivity and non-
High on-treatment clopidogrel platelet reactivity group. At 1-year
